Biblio

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

E

Lewis EMA, Kaushik K, Sandoval LA, Antony I, Dietmann S, Kroll KL. Epigenetic regulation during human cortical development: seq-ing answers from the brain to the organoid. Neurochem Int. 2021:105039.

Yang F-C, Agosto-Peña J. Epigenetic regulation by ASXL1 in myeloid malignancies. Int J Hematol. 2023.

Yang Y, Ma B, Chen J, Liu D, Ma J, Li B, Hao J, Zhou X. Epigenetic regulation and factors that influence the effect of iPSCs-derived neural stem/progenitor cells (NS/PCs) in the treatment of spinal cord injury. Clin Epigenetics. 2024;16(1):30.

Ge W, Liu Y, Chen T, Zhang X, Lv L, Jin C, Jiang Y, Shi L, Zhou Y. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1. Biomaterials. 2014.

Hu M, Schultz RM, Namekawa SH. Epigenetic programming in the ovarian reserve. Bioessays. 2023:e2300069.

Meng Y, Carrelha J, Drissen R, Ren X, Zhang B, Gambardella A, Valletta S, Thongjuea S, Jacobsen SEirik, Nerlov C. Epigenetic programming defines haematopoietic stem cell fate restriction. Nat Cell Biol. 2023.

Alsayed RKhaled ME, Sheikhan KSultan AM, Alam MAli, Buddenkotte J, Steinhoff M, Uddin S, Ahmad A. Epigenetic programing of cancer stemness by transcription factors-non-coding RNAs interactions. Semin Cancer Biol. 2023.

Lin Q, Chauvistré H, Costa IG, Gusmao EG, Mitzka S, Hänzelmann S, Baying B, Klisch T, Moriggl R, Hennuy B, et al. Epigenetic program and transcription factor circuitry of dendritic cell development. Nucleic Acids Res. 2015.

Bruschi M. The Epigenetic Progenitor Origin of Cancer Reassessed: DNA Methylation Brings Balance to the Stem Force. Epigenomes. 2020;4(2).

McCarrey JR. Epigenetic priming as a mechanism of predetermination of spermatogonial stem cell fate. Andrology. 2022.

Tay EXue Yun, Chia K, Ong DSek Tong. Epigenetic plasticity and redox regulation of neural stem cell state and fate. Free Radic Biol Med. 2021.

Allen BK, Stathias V, Maloof ME, Vidovic D, Winterbottom EF, Capobianco AJ, Clarke J, Schurer S, Robbins DJ, Ayad NG. Epigenetic Pathways and Glioblastoma Treatment: Insights From Signaling Cascades. J Cell Biochem. 2014.

Bruno S, Schlaeger TM, Del Vecchio D. Epigenetic OCT4 regulatory network: stochastic analysis of cellular reprogramming. NPJ Syst Biol Appl. 2024;10(1):3.

Drexler R, Khatri R, Sauvigny T, Mohme M, Maire CL, Ryba A, Zghaibeh Y, Dührsen L, Salviano-Silva A, Lamszus K, et al. Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability. bioRxiv. 2023.

Arai Y, Nishino K. Epigenetic mutagen-like environmental chemicals alter neural differentiation of human induced pluripotent stem cells. J Toxicol Sci. 2023;48(11):571-583.

Momparler RL, Côté S, Momparler LF. Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy. Epigenomes. 2020;4(1).

Douvaras P, Rusielewicz T, Kim KHye, Haines JD, Casaccia P, Fossati V. Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes. Int J Mol Sci. 2016;17(4).

Duncan HF, Smith AJ, Fleming GJP, Cooper PR. Epigenetic modulation of dental pulp stem cells: implications for regenerative endodontics. Int Endod J. 2015.

Haladyna JN, Yamauchi T, Neff T, Bernt KM. Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics. 2015;7(2):301-320.

Alexanian AR, Stoellinger HMarie, Farias Vde Araujo, Quiñones-Hinojosa A. Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibit moderate effect on normal stem cells growth. Invest New Drugs. 2023.

Sharma S, Bhonde R. Epigenetic modifiers as game changers for healthy ageing. Rejuvenation Res. 2023.

Zych J, Stimamiglio MA, Senegaglia AC, Brofman PRS, Dallagiovanna B, Goldenberg S, Correa A. The epigenetic modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells. Braz J Med Biol Res. 2013;46(5).

Xu Q, Li Y, Jing Y, Lv N, Wang L, Li Y, Yu L. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2019.

Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q, Tao Q. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget. 2016.

Kubota Y, Nagano H, Kosaka K, Ogata H, Nakayama A, Yokoyama M, Murata K, Akita S, Kuriyama M, Furuyama N, et al. Epigenetic modifications underlie the differential adipogenic potential of preadipocytes derived from human subcutaneous fat tissue. Am J Physiol Cell Physiol. 2021.

Pages